No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CRBU Caribou Biosciences
- 2.020
- +0.140+7.45%
Close Jul 12 16:00 ET
- 2.000
- -0.020-0.99%
Post 19:46 ET
182.44MMarket Cap-1463P/E (TTM)
2.065High1.920Low2.60MVolume1.940Open1.880Pre Close5.21MTurnover3.76%Turnover RatioLossP/E (Static)90.32MShares8.33052wk High0.53P/B139.67MFloat Cap1.50052wk Low--Dividend TTM69.15MShs Float32.645Historical High--Div YieldTTM7.71%Amplitude1.500Historical Low2.004Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Caribou Biosciences Announces Appointment of Terri Laufer, Md, to Its Scientific Advisory Board
Express News | Caribou Biosciences Inc : RBC Cuts Target Price to $14 From $19
Caribou Biosciences Announces Appointment of Terri Laufer, MD, to Its Scientific Advisory Board
-- Dr. Laufer is an immunologist advancing the scientific understanding and treatment of autoimmune diseases -- BERKELEY, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq:
Benign Growth For Caribou Biosciences, Inc. (NASDAQ:CRBU) Underpins Stock's 45% Plummet
Unfortunately for some shareholders, the Caribou Biosciences, Inc. (NASDAQ:CRBU) share price has dived 45% in the last thirty days, prolonging recent pain. The recent drop completes a disastrous tw
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Cuts Target Price to $9
H.C. Wainwright analyst Robert Burns maintains $Caribou Biosciences(CRBU.US)$ with a buy rating, and adjusts the target price from $24 to $9.According to TipRanks data, the analyst has a success rate
Cracking The Code: Understanding Analyst Reviews For Caribou Biosciences
During the last three months, 5 analysts shared their evaluations of Caribou Biosciences (NASDAQ:CRBU), revealing diverse outlooks from bullish to bearish.The table below provides a concise overview o
Comments
$Caribou Biosciences(CRBU.US$
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Caribou Biosciences presented promising clinical data from its CB-010 ANTLER Phase 1 trial at the 2024 ASCO Annual Meeting. CB-010, an allogeneic CAR-T cell therapy with partial HLA matching, showed potential to rival currently approved autologous CAR-T therapies in safety an...
1
$Caribou Biosciences(CRBU.US$ Got a inverted hammer on the daily! Its wick actually broke above the downtrend continuation wedge! Its Really OS RSI 7 = 14.58! RSI 14 = 24.96! MACD Looks as if its fixing to GC? So lets just see how this turns out? Just thinking outloud![]()
3
$Caribou Biosciences(CRBU.US$ Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
Benzinga· 4 mins ago
- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
-- Advancing ANT...
2
Caribou Biosciences' high P/S ratio, despite expected revenue slump and industry's predicted 250% growth, may worry investors. A potential disappointment awaits if the P/S aligns with the negative growth outlook.
Caribou Biosciences' revenue growth is promising but rising cash burn rate could concern investors. Raising more capital may result in shareholder dilution, making the situation risky.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
